腹腔镜肝切除术与微波消融治疗多灶性3-5厘米肝细胞癌的多中心、真实世界研究
Laparoscopic hepatectomy versus microwave ablation for multifocal 3-5 cm hepatocellular carcinoma: a multi-centre, real-world study.
作者信息
Wang Zhen, Pang Chuan, Meng Qiong, Zhang De-Zhi, Hong Zhi-Xian, He Guang-Bin, Yang Hong, Xiang Bang-de, Li Xiao, Jiang Tian-An, Li Kai, Tang Zhe, Huang Fei, Lu Man, Yu Xiao-Ling, Cheng Zhi-Gang, Liu Fang-Yi, Han Zhi-Yu, Dou Jian-Ping, Wu Song-Song, Yu Jie, Liang Ping
机构信息
Departments ofInterventional Ultrasound.
Department of Gynecology, Jinan Zhangqiu District People's Hospital, Jinan.
出版信息
Int J Surg. 2024 Nov 1;110(11):6911-6921. doi: 10.1097/JS9.0000000000001398.
BACKGROUND
Researches comparing laparoscopic liver resection (LLR) with microwave ablation (MWA) for 3-5 cm multifocal hepatocellular carcinoma (MFHCC) are rare.
MATERIALS AND METHODS
From 2008 to 2019, 666 intrahepatic tumours in 289 patients from 12 tertiary medical centres in China were included in this retrospective study. Propensity score matching (PSM) was performed to balance variables between the two treatment groups over time frames 2008-2019 and 2013-2019 to observe the potential impact of advancements in intervention techniques on overall survival (OS), disease-free progression (DFS) of patients. complications, hospitalization, and cost were compared.
RESULTS
Among 289 patients, the median age was 59 years [interquartile range (IQR) 52-66]. 2008-2019, after PSM, the median OS was 97.4 months in the LLR group and 75.2 months (95% CI 47.8-102.6) in the MWA group during a follow-up period of 39.0 months. The 1-year, 3-year and 5-year OS rates in the two groups were 91.8%, 72.6%, 60.7% and 96.5%, 72.8%, 62.5% [hazard ratio (HR) 1.03, 95% CI 0.62-1.69, P =0.920]; The corresponding DFS rates were 75.9%, 57.2%, 46.9%, and 53.1%, 17.5%, 6.2% (HR 0.35, 95% CI 0.23-0.54, P <0.001). 2013-2019, the median OS time was not reached in either group during the 34.0 months of follow-up, the 1-year, 3-year and 5-year OS rates in the two groups were 90.2%, 67.6%, 56.7% and 96.5%, 76.7%, 69.7% (HR 1.54, 95% CI 0.79-3.01, P =0.210); The corresponding DFS rates were 69.6%, 53.9%, 43.3%, and 70.4%, 32.1%, 16.5% (HR 0.68, 95% CI 0.41-1.11, P =0.120). The incidence of major complications was similar in both groups (all P> 0.05). MWA had shorter intervention times, hospitalization, and lower costs.
CONCLUSIONS
For resectable MFHCC patients, LLR is preferable due to its lower recurrence rate. For patients who do not qualify for LLR, advances in ablation technology have promoted MWA as a promising alternative.
背景
比较腹腔镜肝切除术(LLR)与微波消融术(MWA)治疗3 - 5厘米多灶性肝细胞癌(MFHCC)的研究较少。
材料与方法
本回顾性研究纳入了2008年至2019年期间来自中国12家三级医疗中心的289例患者的666个肝内肿瘤。采用倾向评分匹配(PSM)方法,在2008 - 2019年和2013 - 2019年两个时间段内平衡两个治疗组之间的变量,以观察干预技术进步对患者总生存期(OS)、无病进展期(DFS)的潜在影响。比较了并发症、住院情况和费用。
结果
289例患者中,中位年龄为59岁[四分位间距(IQR)52 - 66]。在2008 - 2019年,PSM后,LLR组中位OS为97.4个月,MWA组在39.0个月的随访期内为75.2个月(95%CI 47.8 - 102.6)。两组的1年、3年和5年OS率分别为91.8%、72.6%、60.7%和96.5%、72.8%、62.5%[风险比(HR)1.03,95%CI 0.62 - 1.69,P =0.920];相应的DFS率分别为75.9%、57.2%、46.9%和53.1%、17.5%、6.2%(HR 0.35,95%CI 于0.23 - 0.54,P <0.001)。在2013 - 2019年,两组在34.0个月的随访期内中位OS时间均未达到,两组的1年、3年和5年OS率分别为90.2%、67.6%、56.7%和96.5%、76.7%、69.7%(HR 1.54,95%CI 0.79 - 3.01,P =0.210);相应的DFS率分别为69.6%、53.9%、43.3%和70.4%、32.1%、16.5%(HR 0.68,95%CI 0.41 - 1.11,P =0.120)。两组主要并发症的发生率相似(所有P> 0.05)。MWA组的干预时间、住院时间较短,费用较低。
结论
对于可切除的MFHCC患者,LLR因其较低的复发率更可取。对于不符合LLR条件的患者,消融技术的进步使MWA成为一种有前景的替代方法。